Mapping how genes affect individual brain cells
The BrainCellQTL consortium: QTL mapping in the human brain at the single cell level
This project maps how genetic differences change gene activity in individual brain cells to help people with Alzheimer’s and related dementias.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11309193 on NIH RePORTER |
What this research studies
From my perspective, researchers are combining thousands of single-cell datasets from over 3,000 donated human brains to see how genetic variants change gene activity in specific brain cell types. They will link those cell-type-specific signals to known genetic risk for Alzheimer’s and other brain disorders. By working as a consortium, they can overcome small-sample limits of earlier single-cell studies and find effects that only show up in particular cell types. The work uses existing brain bank samples and advanced single-cell and genetic analysis methods to create a shared resource for the research community.
Who could benefit from this research
Good fit: People with Alzheimer’s or related dementias, or individuals who have arranged to donate brain tissue through a participating brain bank, are most directly connected to this work.
Not a fit: People seeking immediate new treatments should not expect direct, short-term benefits because this project builds foundational knowledge rather than testing a therapy.
Why it matters
Potential benefit: If successful, this could reveal which cell types and genes drive Alzheimer’s risk and point to better diagnostic markers and targets for future treatments.
How similar studies have performed: Early single-cell QTL efforts have shown promising cell-type-specific links to disease risk, but they were small; this consortium greatly increases sample size to improve reliability.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Roussos, Panagiotis — Icahn School of Medicine at Mount Sinai
- Study coordinator: Roussos, Panagiotis
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.